| Symbol | DRMAW |
|---|---|
| Name | DERMATA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 3525 DEL MAR HEIGHTS RD.,#322, SAN DIEGO, California, 92130, United States |
| Telephone | +1 858 - 800-2543 |
| Fax | — |
| — | |
| Website | https://www.dermatarx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001853816 |
| Description | Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Additional info from NASDAQ: |
Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment
Read moreDirector Scott Kathleen D. 🔴 sold 11 shares of Dermata Therapeutics, Inc. (DRMA) at $1.19 Transaction Date: Jun 16, 2026 | Filing ID: 028884
Read moreNew Form S-8 - Dermata Therapeutics, Inc. <b>Filed:</b> 2026-06-04 <b>AccNo:</b> 0001493152-26-027275 <b>Size:</b> 350 KB
Read moreNew Form SCHEDULE 13D - Dermata Therapeutics, Inc. <b>Filed:</b> 2026-06-01 <b>AccNo:</b> 0001493152-26-026642 <b>Size:</b> 12 KB
Read moreNew Form EFFECT - Dermata Therapeutics, Inc. <b>Filed:</b> 2026-05-29 <b>AccNo:</b> 9999999995-26-001810 <b>Size:</b> 1 KB
Read moreNew Form 424B3 - Dermata Therapeutics, Inc. <b>Filed:</b> 2026-05-29 <b>AccNo:</b> 0001493152-26-026446 <b>Size:</b> 404 KB
Read more(99% Neutral) DERMATA THERAPEUTICS, INC. (DRMAW) Announces Executive Changes
Read moreNew Form S-3/A - Dermata Therapeutics, Inc. <b>Filed:</b> 2026-05-22 <b>AccNo:</b> 0001493152-26-025073 <b>Size:</b> 622 KB
Read more(30% Negative) DERMATA THERAPEUTICS, INC. (DRMAW) Reports Q1 2026 Financial Results
Read moreDermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06090721 | DMT310-009 Topical in the Treatment of Acne Vulgaris | Phase3 | Acne Vulgaris | Completed | 2023-12-08 | 2025-04-30 | ClinicalTrials.gov |
| NCT05108025 | DMT310-005 Topical in the Treatment of Acne Rosacea | Phase2 | Acne Rosacea | Unknown | 2021-11-15 | 2022-12-01 | ClinicalTrials.gov |
| NCT04106778 | DMT310-003 Topical in the Treatment of Acne Vulgaris | Phase2 | Acne Vulgaris | Completed | 2019-10-10 | 2020-05-04 | ClinicalTrials.gov |
| NCT03536637 | DMT310-001 Topical in the Treatment of Acne Vulgaris | Phase2 | Acne Vulgaris | Completed | 2018-05-22 | 2019-01-28 | ClinicalTrials.gov |
| NCT03003104 | DMT210 Topical Gel in the Treatment of Acne Rosacea | Phase2 | Acne Rosacea | Completed | 2017-01-01 | 2017-08-30 | ClinicalTrials.gov |
| NCT02949960 | DMT210 Topical Gel in the Treatment of Atopic Dermatitis | Phase2 | Atopic Dermatitis | Completed | 2016-10-01 | 2017-07-14 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Vehicle Control | Other | Phase PHASE2 | Acne Rosacea | COMPLETED | NCT03003104 |
| DMT210 Topical Gel 5% | Other | Phase PHASE2 | Acne Rosacea | COMPLETED | NCT03003104 |
| Vehicle Control | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT02949960 |
| DMT210 Topical Gel | Other | Phase PHASE2 | Atopic Dermatitis | COMPLETED | NCT02949960 |
| Placebo | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT04106778 |
| DMT310 | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT04106778 |
| Placebo | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT03536637 |
| Hydrogen Peroxide | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT03536637 |
| DMT310 | Other | Phase PHASE2 | Acne Vulgaris | COMPLETED | NCT03536637 |
| Placebo Topical Powder | Other | Phase PHASE2 | Acne Rosacea | UNKNOWN | NCT05108025 |
| Topical Powder | Other | Phase PHASE2 | Acne Rosacea | UNKNOWN | NCT05108025 |
| Placebo | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT06090721 |
| DMT310 | Other | Phase PHASE3 | Acne Vulgaris | COMPLETED | NCT06090721 |